Clinical Trials Logo

Iron Overload clinical trials

View clinical trials related to Iron Overload.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03801889 Withdrawn - Iron Overload Clinical Trials

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Start date: August 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the safety and tolerability of SP-420 and it's efficacy in terms of lowering iron in subjects with Beta-thalassemia or other rare anemias who need regular blood transfusions.

NCT ID: NCT03800446 Withdrawn - Iron-deficiency Clinical Trials

Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood

FerPOC
Start date: September 2019
Phase: N/A
Study type: Interventional

Measurement of iron is important for identifying both low and high iron levels in the body. Measuring a protein in the blood called ferritin is currently the easiest way to determine a patient's iron status. However, the test requires a blood sample that is be sent to the laboratory for measurement, which can cause delays in obtaining the result. The investigators are testing whether a point of care device that measures ferritin levels using a capillary blood sample is accurate compared to current methods of testing. This could allow measurement of ferritin immediately in the clinic with only a drop of blood, and enable treatment decisions based on these results.

NCT ID: NCT03141398 Withdrawn - Lymphoma Clinical Trials

Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology Group

CGMs
Start date: August 2017
Phase: N/A
Study type: Observational

A prospective, observational, comparative study with no intervention.The objective of the study to compare the efficiency of detecting glycemic abnormalities using Continuous Glucose Monitoring (CGMs) versus Oral Glucose Tolerance Test (OGTT) and HbA1C (Glycated Hemoglobin) and their relation to iron overload detected by T2* MRI of the pancreas in high-risk patients due to insulin deficiency (potential beta cell injury) and those with insulin resistance and to study the different factors that may affect the glycemic control in these patients in relation to their results like the Dose of corticosteroids and chemotherapy in ALL and Hemoglobinopathies, Liver function in ALL and Hemoglobinopathies, and Serum ferritin in Hemoglobinopathies and their transfusion status. Using Validated Tools with Permission, the participants will be selected through probability (random) sampling method with expected subjects numbers ALL/L: 30-50, Thalassemia Major: 20, Sickle cell disease: 20.

NCT ID: NCT01927913 Withdrawn - Metabolic Diseases Clinical Trials

Treatment of Iron Overload Requiring Chelation Therapy

Start date: November 20, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this open-label study is to assess liver iron concentration using MRI imaging in subjects with beta-thalassemia when administered with either SPD602 or deferasirox for the treatment of chronic transfusional iron overload.

NCT ID: NCT01892644 Withdrawn - Clinical trials for Myelodysplastic Syndromes

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

DefeHEMY
Start date: May 2013
Phase: Phase 2
Study type: Interventional

Hypothesis: Deferasirox can be used as a therapeutic agent to deplete the liver, heart and bone marrow of excess iron in patients with iron overload caused by myelodysplastic syndrome (MDS) and hemochromatosis (HC. Assess the effect of new serum biomarkers (NTBI and hepcidin) and MRI as indicators of iron overload and their usefulness to monitor iron depletion treatment. Study the effect of iron overload and iron depletion on intracellular signal transduction, trace metals concentrations in serum and urine and markers of oxidative stress in blood cells and urine.